Crackdown on Illegal Sale of Anesthetic-Laced E-cigarette Pods

Regulations by 2FIRSTS.ai
Mar.14.2024
Crackdown on Illegal Sale of Anesthetic-Laced E-cigarette Pods
Hubei police cracked down on a major crime case involving cross-provincial trafficking of etomidate, seizing over 380 e-cigarette pods.

Recently, the police in Chongyang County, Hubei Province, successfully cracked a major cross-province criminal case involving the trafficking of Methylone. A total of 7 suspects have been criminally detained, and over 380 e-cigarette pods containing Methylone have been confiscated.

 

Propofol, a white powder substance mainly used for general anesthesia induction and short-term surgical anesthesia, has been increasingly abused by young people in recent years after unscrupulous individuals have added it to e-cigarettes for sale.

 

Therefore, the State Drug Administration, Ministry of Public Security, and National Health Commission jointly issued the "Notice on Adjusting the Catalogue of Narcotic Drugs and Psychotropic Drugs" (No. 120 of 2023), which will be implemented starting from October 1, 2023, including the inclusion of methoxyflurane in the second category of psychotropic drugs. Despite this measure being in effect, the momentum of e-cigarettes containing methoxyflurane in their production and sale does not seem to have diminished.

 

Apart from the harm to one's health, the abuse of Etizolam has been defined as an illegal act by law, with legal consequences similar to those of other drugs, including administrative detention, community rehab, and mandatory isolation for drug detoxification.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Russia May Allow Regions to Introduce Experimental Vape Sales Bans
Russia May Allow Regions to Introduce Experimental Vape Sales Bans
Russia’s government commission on legislative activity has approved second-reading amendments to a bill on licensing trade in tobacco and nicotine-containing products that would allow Russian regions to introduce experimental bans on vape sales.
Mar.31 by 2FIRSTS.ai
PMI’s Smoke-Free Business Accounts for 43% of Net Revenues in Q1 as Full-Year EPS Guidance Rises
PMI’s Smoke-Free Business Accounts for 43% of Net Revenues in Q1 as Full-Year EPS Guidance Rises
On April 22, 2026, Philip Morris International released its first-quarter 2026 results. The report showed net revenues of $10.146 billion, up 9.1% year on year; adjusted diluted EPS of $1.96, up 16.0%; and smoke-free products accounting for 43% of total net revenues. Based on first-quarter performance, the company raised its 2026 full-year adjusted diluted EPS forecast to $8.36 to $8.51, or $8.11 to $8.26 excluding currency.
Apr.23 by 2FIRSTS.ai
Indonesian Parliament Reviews Narcotics Law Draft, May Include Vape Ban Proposal
Indonesian Parliament Reviews Narcotics Law Draft, May Include Vape Ban Proposal
According to Beritasatu, Commission III of the Indonesian House of Representatives is reviewing the Draft Law on Narcotics and Psychotropics and considering including a proposal from the National Narcotics Agency (BNN) to ban vapes.
Apr.10 by 2FIRSTS.ai
Shunhao Shares Reports 2025 Revenue of RMB 1.188 Billion, While Q1 2026 Net Profit Rises 49.94% and New Tobacco Operations Continue
Shunhao Shares Reports 2025 Revenue of RMB 1.188 Billion, While Q1 2026 Net Profit Rises 49.94% and New Tobacco Operations Continue
Shunhao Shares’ 2025 annual report summary and first-quarter 2026 report show that the company recorded 2025 revenue of RMB 1.188 billion, down 21.78% year on year, while net profit attributable to shareholders rose 30.00% to RMB 58.94 million. In the first quarter of 2026, revenue was RMB 291.51 million, down 10.34% year on year, while attributable net profit rose 49.94% to RMB 19.98 million.
Apr.29 by 2FIRSTS.ai
Tennessee House Advances Bill to Direct Vape Tax Revenue to Youth Nicotine Prevention
Tennessee House Advances Bill to Direct Vape Tax Revenue to Youth Nicotine Prevention
The Tennessee House of Representatives advanced legislation this week aimed at curbing underage use of vapor products. House Bill 2360 would allocate 30% of tax revenue from vapor products to counties to support youth nicotine prevention programs across the state.
Mar.23 by 2FIRSTS.ai
Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Summary Ispire Technology announced a strategic joint venture with Chinese pharmaceutical company Jincheng Pharma to manufacture and commercialize nicotine pouch products. The partnership combines pharmaceutical-grade production capabilities with Ispire’s global regulatory infrastructure and distribution network as the company expands beyond vaping hardware into oral nicotine products.
Business
May.13